Exercise or conversion by John Workman of 335 shares of CONMED subject to Rule 16b-3
| CNMD Stock | USD 74.04 0.88 1.20% |
About 51% of CONMED's shareholders are presently thinking to get in. The analysis of overall sentiment of trading CONMED stock suggests that some investors are interested at this time. The current market sentiment, together with CONMED's historical and current headlines, can help investors time the market. In addition, many technical investors use CONMED stock news signals to limit their universe of possible portfolio assets.
CONMED |
Filed transaction by Conmed Corp director. Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
Read at macroaxis.com
CONMED Fundamental Analysis
We analyze CONMED's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of CONMED using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of CONMED based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Price To Earnings To Growth
Price To Earnings To Growth Comparative Analysis
CONMED is currently under evaluation in price to earnings to growth category among its peers. PEG Ratio indicates the potential value of an equity instrument and is calculated by dividing Price to Earnings (P/E) ratio into earnings growth rate. Most analysts and investors prefer this measure to a Price to Earnings (P/E) ratio because it incorporates the future growth of a firm. The low PEG ratio usually implies that an equity instrument is undervalued; whereas PEG of 1 may indicate that an equity is reasonably priced under given expectations of future growth.
CONMED Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with CONMED stock to make a market-neutral strategy. Peer analysis of CONMED could also be used in its relative valuation, which is a method of valuing CONMED by comparing valuation metrics with similar companies.
Peers
CONMED Related Equities
| ANIK | Anika Therapeutics | 3.02 | ||||
| LUNG | Pulmonx Corp | 2.38 | ||||
| KIDS | Orthopediatrics Corp | 2.32 | ||||
| SIBN | Si Bone | 2.19 | ||||
| OFIX | Orthofix Medical | 2.09 | ||||
| SGHT | Sight Sciences | 2.05 | ||||
| ATEC | Alphatec Holdings | 1.06 | ||||
| STE | STERIS Plc | 0.73 | ||||
| GKOS | Glaukos Corp | 0.67 | ||||
| GMED | Globus Medical | 0.38 | ||||
| LIVN | LivaNova PLC | 0.04 | ||||
| ITGR | Integer Holdings | 0.21 | ||||
| SRDX | SurModics | 0.23 |
Complementary Tools for CONMED Stock analysis
When running CONMED's price analysis, check to measure CONMED's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CONMED is operating at the current time. Most of CONMED's value examination focuses on studying past and present price action to predict the probability of CONMED's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CONMED's price. Additionally, you may evaluate how the addition of CONMED to your portfolios can decrease your overall portfolio volatility.
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets |